Tirtha Kamal Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tirtha Kamal Das has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Ross Leigh Cagan
University of Glasgow
3 shared publications Jessica Esernio
Department of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, New York
1 shared publication- Vivek Ashok Rudrapatna
Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA
1 shared publication
Latest Publications
- 31 July 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (15) , 4344-4359
Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
A key tool of cancer therapy has been targeted inhibition of oncogene-addicted pathways. However, efficacy has been limited by progressive emergence of resistance as transformed cells adapt. Here, we use Drosophila to dissect response to targeted therapies. Treatment with a range of kinase inhibitors led to hyperactivation of overall cellular networks, resulting in emergent resistance and expression of stem cell markers, including Sox2. Genetic and drug screens revealed that inhibitors of histone deacetylases, proteasome, and Hsp90 family of proteins restrained this network hyperactivation. These “network brake” cocktails, used as adjuncts, prevented emergent resistance and promoted cell death at subtherapeutic doses. Our results highlight a general response of cells, transformed and normal, to targeted therapies that leads to resistance and toxicity. Pairing targeted therapeutics with subtherapeutic doses of broad-acting “network brake” drugs may provide a means of extending therapeutic utility while reducing whole body toxicity. Significance: These findings with a strong therapeutic potential provide an innovative approach of identifying effective combination treatments for cancer. Cancer Res; 78(15); 4344–59. ©2018 AACR.
- 31 July 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (15) , 4344-4359
Restraining Network Response to Targeted Cancer Therapies Improves Efficacy and Reduces Cellular Resistance
A key tool of cancer therapy has been targeted inhibition of oncogene-addicted pathways. However, efficacy has been limited by progressive emergence of resistance as transformed cells adapt. Here, we use Drosophila to dissect response to targeted therapies. Treatment with a range of kinase inhibitors led to hyperactivation of overall cellular networks, resulting in emergent resistance and expression of stem cell markers, including Sox2. Genetic and drug screens revealed that inhibitors of histone deacetylases, proteasome, and Hsp90 family of proteins restrained this network hyperactivation. These “network brake” cocktails, used as adjuncts, prevented emergent resistance and promoted cell death at subtherapeutic doses. Our results highlight a general response of cells, transformed and normal, to targeted therapies that leads to resistance and toxicity. Pairing targeted therapeutics with subtherapeutic doses of broad-acting “network brake” drugs may provide a means of extending therapeutic utility while reducing whole body toxicity. Significance: These findings with a strong therapeutic potential provide an innovative approach of identifying effective combination treatments for cancer. Cancer Res; 78(15); 4344–59. ©2018 AACR.
- Open Access
- 1 September 2017
- Published by Elsevier in Cell Reports
- Vol. 20 (10) , 2368-2383
KIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub
- 1 September 2017
- Published by Elsevier in Cell Reports
- Vol. 20 (10) , 2368-2383
Open AccessKIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub
- Open Access
- 28 October 2011
- Published by Wiley in Developmental Dynamics
- Vol. 241 (1) , 107-118
Drosophila cancer models
Cancer is driven by complex genetic and cellular mechanisms. Recently, the Drosophila community has become increasingly interested in exploring cancer issues. The Drosophila field has made seminal contributions to many of the mechanisms that are fundamental to the cancer process; several of these mechanisms have already been validated in vertebrates. Less well known are the Drosophila field's early direct contributions to the cancer field: some of the earliest tumor suppressors were identified in flies. In this review, we identify major contributions that Drosophila studies have made toward dissecting the pathways and mechanisms underlying tumor progression. We also highlight areas, such as drug discovery, where we expect Drosophila studies to make a major scientific impact in the future. Developmental Dynamics 241:107–118, 2012. © 2011 Wiley Periodicals, Inc
- 28 October 2011
- Published by Wiley in Developmental Dynamics
- Vol. 241 (1) , 107-118
Open AccessDrosophila cancer models
Cancer is driven by complex genetic and cellular mechanisms. Recently, the Drosophila community has become increasingly interested in exploring cancer issues. The Drosophila field has made seminal contributions to many of the mechanisms that are fundamental to the cancer process; several of these mechanisms have already been validated in vertebrates. Less well known are the Drosophila field's early direct contributions to the cancer field: some of the earliest tumor suppressors were identified in flies. In this review, we identify major contributions that Drosophila studies have made toward dissecting the pathways and mechanisms underlying tumor progression. We also highlight areas, such as drug discovery, where we expect Drosophila studies to make a major scientific impact in the future. Developmental Dynamics 241:107–118, 2012. © 2011 Wiley Periodicals, Inc